AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
- Details
- Category: AstraZeneca
AstraZeneca announced today that it has entered into a definitive agreement to acquire Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Boehringer Ingelheim pioneers biopharmaceuticals move to China
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers.
FDA grants Priority Review to Bristol-Myers Squibb and AstraZeneca's Metreleptin
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has accepted and granted a Priority Review designation for the Biologics License Application (BLA) for metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD), a rare disease estimated to affect a few thousand people around the world, often with an early age of onset.
Sanofi provides update on Phase 3 studies of two investigational compounds
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studies of its investigational compounds iniparib and otamixaban respectively.
Amgen and Astellas announce Japan Alliance
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN), the world's largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas"), a leading Tokyo-based global pharmaceutical company, announced the companies have entered into a strategic alliance to provide new medicines to help address serious unmet medical needs of Japanese patients.
Novartis launches a new campaign to raise awareness of MS
- Details
- Category: Novartis
Today Novartis is joining the global multiple sclerosis (MS) community in celebration of World MS Day by launching a new campaign and participating in initiatives that encourage information and experience exchange around MS. Novartis is committed to supporting the MS community through these initiatives, in addition to delivering and researching innovative treatments to help address the high unmet medical needs of people with MS at every stage of the disease.
AstraZeneca to acquire Omthera Pharmaceuticals including NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio
- Details
- Category: AstraZeneca
AstraZeneca has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialisation of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
More Pharma News ...
- Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"
- Vortioxetine, a new multimodal agent in development for the treatment of major depression
- AstraZeneca issues update on accelerated oncology pipeline
- GSK and Save the Children form unique partnership to save the lives of one million children
- Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
- Amgen and Zhejiang Beta Pharma announce planned joint venture in China
- Boehringer Ingelheim joins Structural Genomics Consortium